• 点赞
  • 1
  • 收藏

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

seekingalpha2022-07-06

Grandbrothers The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG). PG is a rare disorder ...

网页链接

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论1

 
 
 
 

热议股票

 
 
 
 
 

7x24